Cullinan Oncology (NASDAQ:CGEM) PT Raised to $43.00

Cullinan Oncology (NASDAQ:CGEM) had its target price upped by Morgan Stanley from $40.00 to $43.00 in a research report released on Monday morning, Price Targets.com reports. The firm currently has an overweight rating on the stock.

Several other analysts have also commented on the stock. HC Wainwright raised their price target on shares of Cullinan Oncology from $48.00 to $55.00 and gave the company a buy rating in a research report on Friday, June 4th. SVB Leerink raised their price target on shares of Cullinan Oncology from $48.00 to $54.00 and gave the company an outperform rating in a research report on Friday, June 4th.

NASDAQ:CGEM opened at $32.21 on Monday. The firm has a market capitalization of $1.40 billion and a price-to-earnings ratio of -5.88. Cullinan Oncology has a 1-year low of $26.57 and a 1-year high of $59.85. The business has a fifty day simple moving average of $31.80.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Ikarian Capital LLC acquired a new stake in shares of Cullinan Oncology in the first quarter valued at about $42,000. Royal Bank of Canada acquired a new stake in shares of Cullinan Oncology in the first quarter valued at about $52,000. Citigroup Inc. acquired a new stake in shares of Cullinan Oncology in the first quarter valued at about $103,000. UBS Group AG acquired a new stake in shares of Cullinan Oncology in the first quarter valued at about $129,000. Finally, Ensign Peak Advisors Inc acquired a new stake in shares of Cullinan Oncology in the first quarter valued at about $208,000. Institutional investors and hedge funds own 71.97% of the company’s stock.

Cullinan Oncology Company Profile

Cullinan Management, Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.

Further Reading: Catch-Up Contributions

Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.